baber/WOPTO huggingface dataset:
Patent NZ-275673-A (NZ)
Title: Use of phenylacetic acid derivatives optionally in combination with other therapeutic agents for treating neoplastic conditions
Inventor: SAMID DVORIT
IPC: A61K38/21
Filed: 1994-10-12
Abstract: A phenylacetic acid derivative, a salt or stereoisomer or mixture thereof is used in the manufacture of a medicament for treating neoplastic conditions in a mammal, for modulating lipid metabolism, for sensitizing a subject to radiation therapy or for reducing serum triglycerides. A retinoid, hydroxyurea or a mevalonate pathway inhibitor can be included with the phenylacetic acid derivative. The inhibitor can be a vastatin or a terpene and the retinoid can be 9-cis-retinoic acid. T
Patent NZ-289918-A (NZ)
Title: Air deodoriser; comprises a gelified element formed by cross-linking a functionalised liquid polymer and a crosslinking ligand in the presence of a deodorising base
Inventor: O'LEARY NICHOLAS
IPC: A61L9/12
Filed: 1995-08-08
Abstract: A device for perfuming, deodorising or sanitising ambient air or enclosed spaces comprises a gel, formed by in situ crosslinking of a polymer or copolymer in the presence of a perfuming, deodorising, or sanitising agent, or of a surfactant.
Patent NZ-331398-A (NZ)
Title: Tumor rejection antigens presented by hla-b44 molecules, and uses thereof
Inventor: HERMAN JEAN
IPC: A61K35/14
Filed: 1997-02-05
Abstract: Tumor rejection antigens presented by HLA-244 molecules are described. These peptides are useful in diagnostic and therapeutic methodologies. The tumor rejection antigens are derived from MAGE tumor rejection antigen precursors.
Patent NZ-336598-A (NZ)
Title: Process of incorporating a homogenous distribution of aroma-containing substrate into a beverage by positioning a nozzle exactly coaxially above the distribution aperture
Inventor: RUSHMORE DEAN FREDERICK
IPC: A23L27/28
Filed: 1998-01-13
Abstract: process for incorporating an aroma-containing substrate into a beverage powder. The beverage powder is transported in the form of a moving bed and caused to fall in an annular curtain into a filler for filling the beverage powder into containers. As the beverage powder falls in the annular curtain, the aroma-containing substrate is sprayed onto the beverage powder from a position above the moving bed. This provides a substantially homogenous distribution of the aroma-containing substrate in the beverage powder in the filler.
Patent NZ-502051-A (NZ)
Title: CD154 blockade therapy for therapeutic protein inhibitor syndrome
Inventor: ADELMAN BURT
IPC: A61K38/27
Filed: 1998-06-19
Abstract: Disclosed is a method of suppressing the adverse effects of exogenous protein inhibitor syndrome.  The method comprises the step of administering an effective amount of a CD40:CD154 binding interruptor. Preferably, the CD40:CD154 binding interruptor is a CD154 (CD40L) blocking agent  and is usually a monoclonal antibody which has the antigen specific binding characteristics of the 5c8 antibody produced by ATCC Accession No. HB 10916.
Patent NZ-502323-A (NZ)
Title: Monitoring a fluorescence energy transfer pair during hybridization of first probe labelled with fluorescein to second probe labelled with Cy5 or Cy5.5
Inventor: WITTER CARL T
IPC: C12Q1/68
Filed: 1997-06-04
Abstract: Methods of monitoring hybridisation during polymerase chain reaction are described. These methods are achieved with rapid thermal cycling and the use of double stranded DNA dyes or specific hybridisation probes. A fluorescence resonance energy transfer pair comprising a first probe labeled with fluorescein and a second probe labeled with Cy5 or Cy5.5. A fluorescence resonance energy transfer comprising a donor fluorophore having an emission spectrum and an acceptor fluorophore having an absorption spectrum and extinction coefficient greater than 100,000 M-1cm-1, wherein the donor fluorophore's emission spectrum and the acceptor fluorophore absorption spectrum overlap less than 25%. Methods for quantifying amplified DNA and determining its purity are carried out by analysis of melting and reannealing curves.
Patent NZ-503962-A (NZ)
Title: ACE inhibitor (angiotensin converting enzyme) and MMP (matrix metalloproteinase inhibitor) combinations for treating fibrosis
Inventor: PETERSON JOSEPH THOMAS
IPC: A61K31/223
Filed: 1998-11-10
Abstract: A pharmaceutical composition contains a synergistic combination of an angiotensin converting enzyme inhibitor and a matrix metalloproteinase inhibitor which can be used to treat fibrosis, ventricular dilation and/or heart failure.
Patent NZ-507555-A (NZ)
Title: Phase lock loop frequency synthesis with extended range of fractional divisors
Inventor: MANN STEPHEN IAN
IPC: H03L7/197
Filed: 1999-04-14
Abstract: A frequency synthesizer includes a phase-lock-loop with a programmable frequency divider and a controller that determines the average fractional division values for the divider.  Each division value includes selected integer and fractional parts.  The range of variation of the selected fractional part is not limited to {0,1}.  The fractional part may be negative and may have an absolute value greater than 1.
Patent NZ-513717-A (NZ)
Title: Heterocyclic amine modified siloxanes
Inventor: POLICELLO GEORGE A
IPC: C09K23/54
Filed: 2000-02-16
Abstract: The present invention teaches heterocyclic amine modified siloxanes and their use, a preferred of which is as adjuvants for pesticides. The heterocyclic amine modified siloxanes have siloxane backbones with pendant, terminal or intermediate heterocyclic amine groups, which may contain one or more heteroatoms, i.e., nitrogen, sulfur or oxygen. The heterocyclic amine groups or the siloxane may be functionalized further with alkyl or alkyleneoxide groups.
Patent NZ-514089-A (NZ)
Title: Intranasal delivery of pneumococcal polysaccharide vaccines
Inventor: JONSDOTTIR INGILEIF
IPC: A61K39/09
Filed: 2000-03-10
Abstract: The use of a Streptococcus pneumoniae capsular polysaccharide in combination with a mucosal adjuvant such as cholera toxin or E. coli heat-labile toxin in the manufacture of a medicament for the prevention of diseases induced by S. pneumoniae infections.  The capsular polysaccharide may be conjugated and is suitable for mucosal administration.
Patent NZ-516713-A (NZ)
Title: Cheese coating composition
Inventor: CHASSAGNE MARIE-HELENE
IPC: A23L1/00
Filed: 2000-06-22
Abstract: A cheese coating method, in particular pressed paste cheese, is characterised in that it consists in applying on whole cheeses or cheese portions, a coating composition comprising from 60 wt. % to 100 wt. % of an esterifying product of at least a fatty acid and at least a branched polyol having at least 3 carbon atoms and at least two OH groups.
Patent NZ-519046-A (NZ)
Title: Garden tool
IPC: A01B1/16
Filed: 2002-05-20
Abstract: A plant/weed extraction tool (1) including an elongate, rigid, substantially tubular portion having a rectangular cross-section and having at a first end one or more tapered, ground-cutting edge portions (4, 5) and a slot (6) to receive plant/weed foliage which extends axially away from the first end.
Patent NZ-520141-A (NZ)
Title: Benzenesulphonamide derivatives of phenyl propanoic acid useful for treating cardiovascular diseases
Inventor: LAVIELLE GILBERT
IPC: A61K31/445
Filed: 2002-07-12
Abstract: A compound of formula (I), addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful as a TXA2 receptor antagonist and a 5-HT2 receptor antagonist are disclosed, wherein G represents a group such as -NR1R2 wherein R1 and R2 independently represent a hydrogen atom or an alkyl, cycloalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl or heteroarylalkyl group, or, R1 and R2 together with the nitrogen atom form a heterocycloalkyl group, R3 represents a hydrogen atom or an alkyl or optionally substituted phenyl group, Ra represents a hydroxy group, a linear or branched (C1-C6)alkoxy group or an amino group, Rb and Rc, which may be identical or different, each represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, a hydroxy group or a trihaloalkyl group, m is an integer of from 0 to 1 inclusive, n and q are integers of from 0 to 6 inclusive, p and r are integers of from 1 to 6 inclusive, its enantiomers and diastereoisomers.
Patent NZ-521713-A (NZ)
Title: Combination of carboxyalkylethers with antihypertensives and pharmaceutical use
Inventor: AUERBACH BRUCE JEFFREY
IPC: A61K31/19
Filed: 2001-03-22
Abstract: A pharmaceutical composition comprising: (a) an amount of a carboxyalkylether or a pharmaceutically acceptable acid addition salt thereof; (b) an amount of an antihypertensive agent or a pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier or diluent.
Patent NZ-527064-A (NZ)
Title: Coating with a higher reflection than normal colours in the ultraviolet and near infrared range for negligible solar absorption
Inventor: HUGO GERD
IPC: C09D7/60
Filed: 2002-01-18
Abstract: A coating having a negligible solar absorption is disclosed, which comprises: (a) a binding agent with a transparency greater than 60% in the wavelength range of 300 to 2500 nm of ultraviolet and visible light and in the near infrared wavelength range, which have a transparency of less than 70% and in the thermal infrared range of 5 to 50 mm; (b) first pigments which have a transparency of greater than 70% in the wavelength range of 300 to 2500 nm, which have a particle size having a backscattering of greater than 70% in the near infrared wavelength range of 700 to 1500 nm, and which have a absorption of greater than 40% in the thermal infrared range of 5 to 50 mm; (c) second pigments which absorb spectral-selectivity in the visible light wavelength range of 400 to 700 nm, and/or absorb more than 50% in the entire visible light range of 400 to 700 nm, which have a transparency of greater than 50% in the near infrared spectral range of 700 to 1500 nm, and have a absorption of greater than 40% in the thermal infrared range of 5 to 50 mm; (d) and/or third pigments which absorb spectral-selectivity in the spectral range of visible light wavelength range of 400 to 700 nm, and/or absorb more than 50% in the entire visible light range of 400 to 700 nm, and which are reflective themselves in the near infrared spectral range with a reflection of greater than 50% and have a absorption of greater than 40% in the thermal infrared range of 5 to 50 mm; (e) fillers for reducing the reflective index of the binding agent matrix consisting of hollow microspheres filled with a gas or air and/or air pockets in the binding agent, the particles and/or air pocket size of which have a backscattering of less than 70% in the visible light range of 400 to 700 nm, the backscattering of the first pigment increases by 10% in the near infrared wavelength range of 700 to 1500 nm, and which have a absorption of greater than 40% in the thermal infrared range of 5 to 50 mm.
Patent NZ-531259-A (NZ)
Title: Homogeneous assay of biopolymer binding by means of multiple measurements under varied conditions
Inventor: ERIKSON GLEN H
IPC: G01N21/76
Filed: 2002-07-15
Abstract: A method for assaying sequence-specific hybridization, said method comprising: providing a target comprising at least one target biopolymer sequence containing nucleobases; providing a probe comprising at least one probe biopolymer sequence containing nucleobases and being 6 to 30 bases long; adding said probe and said target to a binding medium to provide a test sample; applying a first stimulus to said test sample to provide a first stimulated test sample; detecting a first signal from said first stimulated test sample, wherein said first signal is correlated with a binding affinity between said probe and said target; applying a second stimulus to said first stimulated test sample to provide a second stimulated test sample; detecting a second signal from said second stimulated test sample, wherein said second signal is correlated with said binding affinity between said probe and said target; and comparing said first signal and said second signal to accomplish said assaying; wherein: (a) at least one label is provided in said test sample, (b) said first stimulus, said second stimulus, said first signal and said second signal are photonic or electronic, (c) at least one of said first stimulus and said second stimulus is photonic, (d) when said first stimulus and said second stimulus are photonic, an intermediate electronic stimulus is applied to said test sample after said first stimulus and before said second stimulus, (e) said method is conducted without separating probe-target complexes from free probes and targets, and (f) said method assays: (i) quadruplex hybridization between said probe and said target, (ii) homologous triplex hybridization between said probe and said target, or (iii) homologous duplex hybridization between said probe and said target.
Patent NZ-536146-A (NZ)
Title: Method of preparation of high quality soy cultured products
Inventor: AKASHE AHMAD
IPC: A23L5/49
Filed: 2004-10-26
Abstract: A soy-containing fermented product such as yogurt, comprising fermented soy milk prepared by fermenting deflavoured soy milk, wherein the deflavoured soy milk is prepared by a method comprising; (a) obtaining a soy milk composition containing soluble soy proteins, flavouring compounds, and insoluble materials; (b) solubilizing the soy proteins by adjusting the soy milk composition of (a) to a pH in the right of about 9 to about 12 and releasing the flavouring compounds; (c) passing the pH-adjusted soy milk composition of (b) adjacent to an ultrafiltration membrane having a molecular weight cutoff up to about 50,000 Daltons, while maintaining the pH in the range of about 9 to about 12, under suitable ultrafiltration conditions wherein the flavour compounds pass through the membrane, thereby deflavouring the soy milk composition and retaining substantially all of the solubilized soy proteins; and (d) recovering the solubilized soy proteins retained by the ultrafiltration membrane, wherein the recovered solubilized soy proteins is the deflavoured soy milk. Also described is a method of preparing a soy-containing fermented product comprising: (1) preparing a mixture of deflavoured soy milk material and an effective amount of a starter culture; and (2) fermenting the mixture to form the soy-containing fermented product; wherein the deflavoured soy milk material is prepared by the described method above in steps (a), (b) and (c).
Patent NZ-537382-A (NZ)
Title: Extracorporeal photopheresis in combination with anti-TNF treatment
Inventor: PERRITT DAVID
IPC: A61K35/14
Filed: 2004-12-22
Abstract: Disclosed is the use of a TNF-alpha antagonist in the preparation of a medicament for the treatment of an autoimmune disease or the amelioration of one or more symptoms thereof in a subject in need thereof, wherein the medicament further comprises a population of cells that has been subjected to an apoptosis-inducing treatment.
Patent NZ-540767-A (NZ)
Title: Treatment of diseases and conditions mediated by increased phosphorylation
Inventor: BAR-OR DAVID
IPC: A61K38/08
Filed: 2003-11-25
Abstract: Disclosed are methods for the treatment of diseases and conditions mediated by increased phosphorylation, such as inflammation and cancer. The invention also provides methods for the inhibition of increased phosphorylation in cells, tissues and organs. The methods utilize a phosphate acceptor compound (PAC). The invention also provides products comprising a PAC, in particular phosvitin or a functional fragment thereof.
Patent NZ-542600-A (NZ)
Title: Water heater/cooler with heat-conductive material between tube and wall of tank, and layer of material wrapped about tank in airtight manner
Inventor: STEVENS RODNEY
IPC: F24D3/08
Filed: 2004-03-24
Abstract: Disclosed is a water heater/cooler (10) having a water tank (12) with a wall (18) formed from material having heat transfer properties. A tube (24) which carries a refrigerant fluid is applied externally about tank wall (18). A heat-conductive material is coextensive with the length of tube (24) to allow tube (24) to be in heat-conductive contact with tank wall (24). At least one layer of material is tightly wrapped about tank wall (18) and tube (24).
Patent NZ-543395-A (NZ)
Title: Controlled release formulation of erythromycin derivatives
Inventor: MULYE NIRMAL
IPC: A61K/
Filed: 2004-05-06
Abstract: Provided is a controlled release formulation in tablet form comprising a pharmaceutically effective amount of an erythromycin derivative and a lubricating effective amount of a lubricant in the absence of a material selected from the group consisting of alginic acid or salts thereof or hydrophilic sustained release polymers being present in concentrations effective to retard the release of the erythromycin derivatives from the pharmaceutical composition. Also provided is the corresponding method of facilitating the release of an erythromycin derivative from a pharmaceutical composition in a tablet form.
Patent NZ-547857-A (NZ)
Title: Session-by-session adjustment of a device for treating sleep disordered breathing
Inventor: FARRUGIA STEVEN PAUL
IPC: A61M16/00
Filed: 2005-02-10
Abstract: A system for treating sleep disordered breathing (SOB) during successive treatment sessions is disclosed. The system provides continuous positive airway pressure during sleep. The system includes a blower, a blower controller, a mask for communicating pressurized air between the blower and a patient, and a mechanism for allowing the controller to derive signals indicative of pressure and flow. The controller controls a constant treatment pressure applied during a first session. The controller then derives a sleep disorder index (SOI) representative of the number of SOB episodes that occurred during the first session, and based on the SOI, determines if an adjustment in treatment pressure is required. The controller then controls an adjustment in the treatment pressure during a second, subsequent session if it was determined that an adjustment is required. The first and second sessions are separate in that the blower is turned off between the sessions.
Patent NZ-552290-A (NZ)
Title: Tablet fomulation
Inventor: AL ALAWI FADIL
Filed: 2006-12-21
Abstract: Provided is a method of producing a tablet including at least one macrocyclic lactone compound having anthelmintic activity formulated for administration to an animal characterised by the steps of a) dissolving the macrocyclic lactone compound or compounds in at least one organic solvent and; b) then subsequently mixing the mixture of (a) with at least one co-solvent selected from an alcohol or ether compound with three or more carbon atoms, or combinations thereof, prior to tablet formation. Further provided are tablets produced by the method and kits containing the tablets as well as methods of treating non-human animals with the tablets for parasite infestation.
Patent NZ-553487-A (NZ)
Title: Method of wound healing using A2B adenosine receptor antagonists
Inventor: ZENG DEWAN
IPC: A61K31/522
Filed: 2005-08-30
Abstract: Disclosed are compounds of formula I and II, adenosine A2B receptor antagonists, used for accelerating wound healing.
Patent NZ-560849-A (NZ)
Title: Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
Inventor: TACHDJIAN CATHERINE
IPC: A23L27/26
Filed: 2006-02-06
Abstract: Disclosed is a compound of Formula (IA) or a comestibly acceptable salt thereof, wherein n', n", hAr1 and hAr2 is defined in the specification. Also disclosed is a composition comprising said compound and a method for modulating savory taste comprising said compound.
Patent NZ-565363-A (NZ)
Title: Pyrrolo[2,3-D]pyrimidine derivatives; their intermediates and synthesis
Inventor: RUGGERI SALLY GUT
IPC: C07D211/56
Filed: 2006-07-17
Abstract: A method of making a pyrrolo [2,3-d] pyrimidine compound of the Formula Iva comprising coupling an activated pyrrolopyrimidine compound of the Formula (lIa) wherein L1 is a leaving group and X1 is an activating group; with an amine of the Formula (lIla), or a salt thereof; wherein R1 is (C1 -C5)alkyl; a is an integer from 0 to 4; R2 is hydrogen or (C1 - C5) alkyl and P is a nitrogen protecting group; in the presence of a base to afford a coupled product of the Formula (IVa). Specifically novel synthetic methods and intermediates for the synthesis of 3- {(3R, 4R)-4-methyl-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-amino}-piperidin-l-yl)-3-oxo-propionitrile and its corresponding citrate salt are disclosed.
Patent NZ-565503-A (NZ)
Title: A method for recovery of high purity carbon dioxide from a gaseous source comprising nitrogen compounds
Inventor: FIND RASMUS
IPC: C01B32/50
Filed: 2006-07-14
Abstract: Disclosed is a method for recovery of carbon dioxide from a gaseous source comprising the steps of: a. feeding a gas (G1) comprising carbon dioxide, oxygen, and nitrogen compounds into an absorption column (A1), b. absorbing the gas (G1) in an alkanolamine-containing absorbing agent, by which the gas (G1) is separated into a carbon dioxide depleted gas (G2) and a carbon dioxide-rich liquid (L1), c. pressurising and heating the liquid (L1) obtained in step b in order to provide the liquid (L2), d. separating by means of flashing the liquid (L2) obtained in step c into a NOx- and oxygen-rich gas (G3) and a NOx- and oxygen depleted liquid leaving the flash column (A3), e. pressurising the liquid leaving the flash column (A3) in step d in order to provide the liquid (L3), f. separating the liquid (L3) obtained in step e into a carbon dioxide-rich gas (G4) and a carbon dioxide-depleted liquid (L4) by means of stripping, and g. purifying the gas (G4) obtained in step f in order to produce carbon dioxide, which is substantially free of nitrogen oxides. Also disclosed is the use of the method in the production of carbon dioxide and carbon dioxide produced by the method.
Patent NZ-566520-A (NZ)
Title: Therapy with CD4 binding peptides and radiation
Inventor: PARREN PAUL
IPC: A61K31/00
Filed: 2006-08-18
Abstract: Provided is the use of an anti-CD4 antibody or antigen binding fragment thereof and a psoralen in the manufacture of a medicament for the treatment of a CD4+ T-cell mediated condition selected from the group consisting of primary cancer, metastatic cancer and inflammatory skin disease in a subject, and wherein the anti-CD4 antibody is zanolimumab or an anti-CD4 antibody or antigen binding fragment thereof comprising all six CDR sequences of the antibody zanolimumab.
Patent NZ-567184-A (NZ)
Title: Auto-injected device with needle protecting cap having outer and inner sleeves
Inventor: HABESHAW ROSIE LOUISE
IPC: A61M5/20
Filed: 2005-09-27
Abstract: An injection device is described having a housing (112) that receives a syringe (not shown) having a sealed boot that covers its needle. A releasable locking mechanism (not shown) retains the syringe in its retracted position. A sleeve (119) projects from the exit aperture (128) and can be depressed to release the locking mechanism. A removable threaded cap (111) closes the housing (112), covers the exit aperture (128) and the sleeve (119), thus preventing the locking mechanism from being released, and engages the boot on the syringe. When the cap (111) is removed, it takes the boot with it, no longer closes the exit aperture (128) and no longer prevents the locking mechanism from being released. Then, the locking mechanism can be released and the injection cycle begun.